Many cancer treatments frequently fall short of the anticipated results. The ability of tumours to acquire resistance to cancer treatments is a frequent explanation for this. Alpelisib, a medication licenced in Switzerland for the treatment of advanced breast cancer, is one example. Alpelisib responsiveness is reduced by the absence of the NF1 gene, according to the University of Basel’s Department of Biomedicine.
The study team found that the dietary supplement N-acetylcysteine can enhance the sensitivity of cancer cells to the treatment. The scholarly journal Cell Reports Medicine recently reported these findings.
Resistance is triggered by gene loss
There are currently few viable therapeutic options available for patients with advanced and metastatic breast cancer. Breast cancer frequently has an overactive PI3K signalling system because of mutations that encourage tumour growth. Therefore, the approval of the PI3K inhibitor Alpelisib was eagerly awaited.
According to Professor Mohamed Bentires-Alj, leader of the research team, “Unfortunately, it turned out that resistance is severely limiting the success of the medication.” “Therefore, we must learn more quickly about how resistance develops.”
In order to determine which genes had mutated to make cancer cells resistant, his team set out to identify the genetic basis of the resistance. As a result, the tumours became resistant to treatment with alpelisib due to mutations that turned off the NF1 protein’s synthesis.
An effective combination with an expectorant
An analysis found that the loss of NF1 impacts the cell’s energy stores. “They stop producing as much energy using mitochondria; instead, they switch to other energy production pathways,” said the study’s principal author, Dr. Priska Auf der Maur.
Given these modifications, the researchers tested the impacts of NF1 depletion using the well-known antioxidant N-acetylcysteine, which has a comparable impact on energy metabolism. This chemical is a popular nutritional supplement and a common component in cough syrups.
Contrary to expectations, N-acetylcysteine restored the efficacy of alpelisib in cancer cells that were resistant to the drug. In fact, it made it worse. The researchers found that this occurs via an extra intervention in a signalling pathway that likewise has a significant impact on tumour growth. It’s interesting to note that drug resistance is also influenced by the depletion of NF1. In these circumstances, a combination therapy with N-acetylcysteine may potentially be an option.
This result is very important for clinical research because N-acetylcysteine is a safe and widely used addition, according to Bentires-Alj. N-acetylcysteine and alpelisib together, in his opinion, could enhance the therapy of advanced breast cancer. To confirm the beneficial effects seen in the lab, clinical trials involving breast cancer patients would now be the next step.
Visit CxO Global FORUM or CxO News Live for all the latest updates.
